Pharmaceutical companies are asking more – and different – of their outsourcing partners at the same time as qualified capacity, regulatory scrutiny, and program complexity are making those partnerships harder to manage.
Artificial intelligence dominated the conversation at CDMO Live Europe 2026. But compared to just a few years ago, the AI discussion is no longer about whether AI belongs in pharmaceutical manufacturing. It’s now
Last month, I attended two events focused on different parts of the pharmaceutical landscape: CDMO Live in Rotterdam and Pharmacovigilance USA in Boston. The conversations ranged from supply chain resilience and outsourcing
Artificial intelligence is quickly becoming one of the most aggressively-pursued investments in biotechnology. The global market for AI in biotech is projected to grow from $4.6 billion in 2025 to $11.4 billion by
Reliant Life Sciences’ Vice President Ben Locwin recently joined host Ross Katz on the Data in Biotech podcast to discuss how artificial intelligence is being applied across drug development, manufacturing and clinical research. The
U.S. biomanufacturing is scaling fast. Faster, in fact, than most organizations are built to handle under regulatory scrutiny. U.S. biomanufacturing pledged investment since 2024, with pharmaceutical and life sciences companies pledging upwards
Biopharma leaders are being asked to do something that is directionally clear but operationally complex: Reshore manufacturing, reduce dependency on overseas production, and strengthen supply chain resilience. That pressure is coming from
When HHS Secretary Robert F. Kennedy Jr. abruptly terminated 22 federal mRNA vaccine contracts—worth a combined $500 million—the biotech sector was left reeling. This unprecedented move hits major players like Pfizer, Moderna,
22 Roulston Road
Windham NH 03087
64 E Broadway Rd, Suite 200
Tempe AZ 85282
